If someone had shared five years ago that industry would still be debating AI governance frameworks inside validation steering committees, it would have seemed unlikely. At the time, many genuinely believed the maturation of digital validation, especially with the publication of the

As pharmaceutical manufacturers accelerate digital transformation, many organizations face a familiar challenge: how to adopt modern technologies without increasing compliance risk or operational friction. The 2026 ISPE Europe Annual Conference brings industry leaders together to address exactly this tension—bridging innovation, quality, and regulatory expectations with proven, real-world...

AI is no longer a distant or experimental concept within pharmaceutical and biotechnology organizations. Across laboratories, manufacturing operations, and quality systems, AI-enabled tools are increasingly being piloted to accelerate insights, strengthen decision-making, and improve operational efficiency. Yet despite growing enthusiasm, many organizations encounter a consistent and familiar...

This blog post produced by the ISPE D/A/CH CoP Aseptic Processing – Subgroup Appropriate Technologies, synthesizes regulatory drivers from EU/PIC/S GMP Annex 1 and provides guiding principles for installing sterile format parts into open isolators, presenting stepwise transfer and handling strategies to protect critical surfaces, first air and to ensure product sterility.

Career advancement in the life sciences sector is increasingly shaped by the ability to integrate technical excellence with regulatory rigor and cross functional collaboration. As therapies become more complex and regulatory expectations continue to evolve, professionals must understand how manufacturing decisions, quality systems, and digital infrastructures directly influence product...

Artificial intelligence is no longer a future concept for pharmaceutical development and manufacturing—it is an active, rapidly evolving capability with real implications for quality, safety, and regulatory expectations. The latest ISPE podcast episode examines AI at the intersection of regulatory guidance and pharmaceutical innovation, featuring insights from two seasoned leaders: David...

The 2026 ISPE Europe Annual Conference in Copenhagen, Denmark, is set to highlight some of the most recent Guidance Documents to be published by ISPE. This year’s ISPE Spotlight Sessions, held in the ISPE Publications Lounge within the exhibits area, will feature five focused presentations during lunch and networking breaks on Monday, 20 April; Tuesday, 21 April; and Wednesday, 22 April.

As one of ISPE Shanghai’s most significant annual gatherings, the 2026 ISPE China Annual Conference, held on 21–22 May 2026, in Shanghai, China, is designed to convene industry leaders, regulatory authorities, engineers, researchers, technology providers, and other key stakeholders from across the pharmaceutical sectors. The event will provide a comprehensive platform for dialogue,...

Good manufacturing practices (GMP form the foundation of pharmaceutical quality, safety, and regulatory compliance. Every person working in pharmaceutical development, manufacturing, packaging, engineering, quality control (QC), quality assurance (QA), and support functions plays a vital role in ensuring that every product released to patients is safe, pure, and effective.

Connecting the information technology (IT)/operational technology (OT) dots can sound complicated, but when intelligent systems start communicating in a common language, connecting things together becomes remarkably straightforward.

Pharmaceutical laboratories are embarking on a digital transformation journey to bridge data integrity (DI) gaps, modernize operations and enhance efficiency. A key aspect of this evolution is transitioning from paper-based records to streamlined digital workflows, a shift that addresses unique challenges for simple, firmware-driven instruments that can be widely used across global lab...

Innovation continues to redefine what is possible across the pharmaceutical and biomanufacturing landscape. From AI-enabled efficiency gains to next-generation facility design, the industry is accelerating toward more adaptive, resilient, and sustainable manufacturing models.

Global clinical trials play a vital role in advancing medical research and improving patient care worldwide. The nature and scope of clinical research has changed significantly over the past decade: trials have become more complex, new delivery methods have been established as the landscape for drug development continues to evolve. Against a backdrop of an unpredictable and disruptive global...

Bioreactor scale-up remains one of the most critical challenges in pharmaceutical manufacturing. Traditionally, the industry has approached this challenge through the lens of engineering equivalence, focusing on matching normalized parameters across development and manufacturing scales. Common strategies include maintaining power per unit volume, impeller tip speed, bulk mixing time, or oxygen...

AI is now part of many daily quality and manufacturing activities. As uses of AI grow, inspectors will expect clear explanations of how AI-enabled systems impact GxP decisions and how companies keep them under control. Inspection readiness becomes essential because AI systems introduce new risks, new types of documentation, and new types of expertise.

A recent episode of the ISPE Podcast: Shaping the Future of Pharma brings together key voices from the...

As regulatory expectations around aseptic manufacturing continue to evolve, Annex 1 has sharpened industry focus on one of the most contamination-sensitive stages of lyophilization: freeze-dryer loading and unloading. Ensuring Grade A continuity, minimizing operator intervention, and preserving unidirectional airflow are no longer aspirational goals—they are baseline requirements that...

The life sciences industry stands at a pivotal moment. Artificial intelligence (AI) and generative models are rapidly moving from experimental environments into GxP-regulated workflows. At the same time, regulatory expectations, including those reflected in the EU Annex 22 Draft and recent US Food and Drug Administration guidance, are evolving, with increased scrutiny on data integrity, model...

The Medicines and Healthcare products Regulatory Agency (MHRA) is leading a transformative shift in pharmaceutical manufacturing with the introduction of the DM framework.

The pharmaceutical industry is undergoing a technological revolution, driven by digital transformation and emerging technologies such as AI/machine learning (ML). These innovations are being applied across the entire product lifecycle from research and development and clinical development to manufacturing, quality assurance, supply chain, and patient support. A critical focus area is the...